Arginase-2 mediates diabetic renal injury

Diabetes

Volumn 60, Issue 11, 2011, Pages 3015-3022

  Morris Jr , Sidney M ^a   Gao, Ting ^b   Cooper, Timothy K ^b   Kepka Lenhart, Diane ^a   Awad, Alaa S ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGINASE 1; ARGINASE 2; CYSTEINE; S (2 BORONOETHYL) LEVO CYSTEINE; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; HISTOPATHOLOGY; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY MEDULLA; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; UREA NITROGEN BLOOD LEVEL;

ALBUMINURIA; ANIMALS; ARGINASE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTIOCYTES; HYPERGLYCEMIA; KIDNEY; MALE; MICE; MICE, INBRED DBA; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; REGIONAL BLOOD FLOW; RNA, MESSENGER; STREPTOZOCIN;

EID: 80755152815     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-0901     Document Type: Article

References (36)

1. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 2010;8:29
2. American Diabetes Association. Position Statement: Diabetic nephropathy. Diabetes Care 2001;24(Suppl. 1):S69-S72
3. USRDS TUSRDS. Annual Data Report. Bethesda, The National Institutes of Diabetes and Digestive and Kidney Diseases, 2001
4. Zhang C, Hein TW, Wang W, Chang CI, Kuo L. Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001;15:1264-1266
5. Berkowitz DE, White R, Li D, et al. Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 2003;108:2000-2006 (Pubitemid 37296546)
6. Lim HK, Lim HK, Ryoo S, et al. Mitochondrial arginase II constrains endothelial NOS-3 activity. Am J Physiol Heart Circ Physiol 2007;293:H3317-H3324 (Pubitemid 350230871)
7. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 2007;34:906-911 (Pubitemid 47083958)
8. Grönros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 2011;300:H1174-H1181
9. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol 2011;300:H777-H783
10. Toque HA, Tostes RC, Yao L, Xu Z, Webb RC, Caldwell RB, Caldwell RW. Arginase II deletion increases corpora cavernosa relaxation in diabetic mice. J Sex Med 2011;8:722-733
11. Romero MJ, Platt DH, Tawfik HE, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008;102:95-102
12. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol 2009;157:922-930
13. Morris SM Jr, Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol 1998;275:E740-E747
14. Gotoh T, Sonoki T, Nagasaki A, Terada K, Takiguchi M, Mori M. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett 1996;395:119-122 (Pubitemid 26356167)
15. Vockley JG, Jenkinson CP, Shukla H, Kern RM, Grody WW, Cederbaum SD. Cloning and characterization of the human type II arginase gene. Genomics 1996;38:118-123 (Pubitemid 26424589)
16. Morris SM Jr, Bhamidipati D, Kepka-Lenhart D. Human type II arginase: sequence analysis and tissue-specific expression. Gene 1997;193:157-161 (Pubitemid 27294602)
17. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1-17 (Pubitemid 28532555)
18. Breyer MD, Böttinger E, Brosius FC 3rd, et al.; AMDCC. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2005;16:27-45 (Pubitemid 43073154)
19. Brosius FC 3rd, Alpers CE, Bottinger EP, et al.; Animal Models of Diabetic Complications Consortium. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009;20:2503-2512
20. Ryoo S, Gupta G, Benjo A, et al. Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res 2008;102:923-932 (Pubitemid 351591553)
21. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008;21:1288-1291
22. Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006;17:2664-2669 (Pubitemid 44484656)
23. Awad AS, Rouse M, Huang L, et al. Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int 2009;75:689-698
24. Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol 2006;290:F1516-F1524 (Pubitemid 43830779)
25. Awad AS, Huang L, Ye H, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol 2006;290:F828-F837 (Pubitemid 43724943)
26. Kepka-Lenhart D, Ash DE, Morris SM. Determination of mammalian arginase activity. Methods Enzymol 2008;440:221-230
27. Shi O, Morris SM Jr, Zoghbi H, Porter CW, O'Brien WE. Generation of a mouse model for arginase II deficiency by targeted disruption of the arginase II gene. Mol Cell Biol 2001;21:811-813 (Pubitemid 32104729)
28. Morris SM Jr. Arginine metabolism: boundaries of our knowledge. J Nutr 2007;137(Suppl. 2):1602S-1609S
29. Levillain O, Balvay S, Peyrol S. Localization and differential expression of arginase II in the kidney of male and female mice. Pflugers Arch 2005;449:491-503 (Pubitemid 40238884)
30. Levillain O, Balvay S, Peyrol S. Mitochondrial expression of arginase II in male and female rat inner medullary collecting ducts. J Histochem Cytochem 2005;53:533-541 (Pubitemid 40463507)
31. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108:1527-1532 (Pubitemid 37176462)
32. Goligorsky MS, Chen J, Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 2001;37:744-748 (Pubitemid 32199060)
33. Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci USA 1996;93:6770-6774
34. Brodsky SV, Gao S, Li H, Goligorsky MS. Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells. Am J Physiol Heart Circ Physiol 2002;283:H2130-H2139 (Pubitemid 35217047)
35. Wang CH, Li F, Hiller S, et al. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci USA 2011;108: 2070-2075
36. Balakumar P, Chakkarwar VA, Krishan P, Singh M. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed Pharmacother 2009;63:171-179